For decades, we've been told “Lower LDL is Better.” But what if, in our myopic obsession with LDL and ApoB, we’ve missed a ...

Please provide your email address to receive an email when new articles are posted on . ApoA-I infusions may improve outcomes after acute heart attack for patients with multivessel CAD and ...

My cholesterol has been on the rise for the past few years – and not just a slow creep. For most of my life, my LDL (often referred to as ‘bad’ cholesterol) was solidly under 120 mg/dl. Over the past ...

Study deciphers the molecular handshake between LDL receptors and apoB100, shedding light on cholesterol metabolism and its role in cardiovascular disease. Study: Structure of apolipoprotein B100 ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

A 4-week trial on 'Navelina' oranges shows potential effects on lipid metabolism in fatty liver disease, revealing intriguing ...